Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/8188| Structural elucidation and antiviral activity of cathepsin L inhibitors with carbonyl and epoxide warheads | |
| Sven Falke Julia Lieske Alexander Herrmann Jure Loboda Sebastian Günther Patrick Reinke Wiebke Ewert Katarina Karnicar Aleksandra Usenik Nataša Lindič Andreja Švajger Hideaki Tsuge Vito Kovač Henry Chapman Winfried Hinrichs Gregor Ebert Dusan Turk Alk Meents | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| https://doi.org/10.1101/2023.08.11.552671 | |
| https://www.biorxiv.org/content/10.1101/2023.08.11.552671v1 | |
| Emerging RNA viruses including SARS-CoV-2 continue to be a major threat around the globe. The cell entry of SARS-CoV-2 particles via the endosomal pathway involves the cysteine protease cathepsin L (CatL) among other proteases. CatL is rendered as a promising drug target in the context of different viral and lysosome-related diseases. Hence, drug discovery and structure-based optimization of inhibitors is of high pharmaceutical interest. We herein verified and compared the anti-SARS-CoV-2 activity of a set of carbonyl and succinyl-epoxide-based inhibitors, which have previously been identified as cathepsin inhibitors. Calpain inhibitor XII (CI-XII), MG-101 and CatL inhibitor IV (CLI-IV) possess antiviral activity in the very low nanomolar IC50 range in Vero E6 cells. Experimental structural data on how these and related compounds bind to CatL are however notably lacking, despite their therapeutic potential. Consequently, we present and compare crystal structures of CatL in complex with 14 compounds, namely BOCA (N-BOC-2-aminoacetaldehyde), CLI-IV, CI-III, CI-VI, CI-XII, the main protease α-ketoamide inhibitor 13b, MG-101, MG-132 as well as E-64d (aloxistatin), E-64, CLIK148, CAA0225, TC-I (CID 16725315) and TPCK at resolutions better than 2 Å. Overall, the presented data comprise a broad and solid basis for structure-guided understanding and optimization of CatL inhibitors towards protease drug development. | |
| bioRxiv | |
| 14-08-2023 | |
| Preimpreso | |
| Inglés | |
| Público en general | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Materiales de Consulta y Comunicados Técnicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Structural elucidation and antiviral activity of cathepsin L inhibitors with carbonyl and epoxide warheads.pdf | 1.5 MB | Adobe PDF | Visualizar/Abrir |